Second Sight Medical Products, Inc. (NASDAQ:EYES) was up 17.5% during trading on Wednesday . The company traded as high as $2.55 and last traded at $2.35. Approximately 3,989,600 shares traded hands during trading, an increase of 617% from the average daily volume of 556,567 shares. The stock had previously closed at $2.00.

A number of equities research analysts have recently commented on EYES shares. Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Second Sight Medical Products in a research note on Monday, November 6th.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 184.87%. The firm had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $1.54 million. equities analysts anticipate that Second Sight Medical Products, Inc. will post -0.55 EPS for the current year.

A hedge fund recently raised its stake in Second Sight Medical Products stock. Vanguard Group Inc. boosted its stake in Second Sight Medical Products, Inc. (NASDAQ:EYES) by 0.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 843,462 shares of the medical device company’s stock after acquiring an additional 5,973 shares during the quarter. Vanguard Group Inc. owned 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent filing with the SEC. 12.75% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.